Adverse effects of dopamine potentiation by long‐term treatment with selegiline
Identifieur interne : 003E24 ( Main/Exploration ); précédent : 003E23; suivant : 003E25Adverse effects of dopamine potentiation by long‐term treatment with selegiline
Auteurs : Susan Hollán [Hongrie] ; Lászl Vécsei [Hongrie] ; Kálmán Magyar [Hongrie]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-01.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adolescent, Adult, Amine oxidase (flavin-containing), Anemia, Hemolytic, Congenital (enzymology), Anemia, Hemolytic, Congenital (genetics), Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Baclofen (adverse effects), Baclofen (therapeutic use), Basal Ganglia (drug effects), Basal Ganglia Diseases (drug therapy), Basal Ganglia Diseases (enzymology), Basal Ganglia Diseases (genetics), Blood Platelets (enzymology), Catecholamine, Dopamine, Dopamine agonist, Drug Therapy, Combination, Dyskinesia, Drug-Induced (diagnosis), Dyskinesia, Drug-Induced (etiology), Dystonia Musculorum Deformans (drug therapy), Dystonia Musculorum Deformans (enzymology), Dystonia Musculorum Deformans (genetics), Enzyme inhibitor, Female, Genotype, Glyceraldehyde-3-Phosphate Dehydrogenases (deficiency), Glyceraldehyde-3-Phosphate Dehydrogenases (genetics), Heterozygote Detection, Humans, Long-Term Care, MAO B inhibitor, Male, Middle Aged, Monoamine Oxidase (blood), Monoamine Oxidase (genetics), Monoamine Oxidase Inhibitors (adverse effects), Monoamine Oxidase Inhibitors (therapeutic use), Nerve Tissue Proteins (genetics), Nervous system diseases, Neurologic Examination (drug effects), Neuroprotective Agents (adverse effects), Neuroprotective Agents (therapeutic use), Nuclear Proteins (genetics), Polymerase Chain Reaction, Potentiation, Proteins (genetics), Psychoses, Substance-Induced (diagnosis), Psychoses, Substance-Induced (etiology), Reference Values, Selegiline, Selegiline (adverse effects), Selegiline (therapeutic use), TPI defect, Treatment, Trinucleotide Repeats, monoamine oxidase‐B, selegiline, triosephosphate isomerase.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Baclofen, Monoamine Oxidase Inhibitors, Neuroprotective Agents, Selegiline.
- chemical , blood : Monoamine Oxidase.
- chemical , deficiency : Glyceraldehyde-3-Phosphate Dehydrogenases.
- diagnosis : Dyskinesia, Drug-Induced, Psychoses, Substance-Induced.
- drug effects : Basal Ganglia, Neurologic Examination.
- drug therapy : Basal Ganglia Diseases, Dystonia Musculorum Deformans.
- enzymology : Anemia, Hemolytic, Congenital, Basal Ganglia Diseases, Blood Platelets, Dystonia Musculorum Deformans.
- etiology : Dyskinesia, Drug-Induced, Psychoses, Substance-Induced.
- genetics : Anemia, Hemolytic, Congenital, Basal Ganglia Diseases, Dystonia Musculorum Deformans, Glyceraldehyde-3-Phosphate Dehydrogenases, Monoamine Oxidase, Nerve Tissue Proteins, Nuclear Proteins, Proteins.
- chemical , therapeutic use : Antiparkinson Agents, Baclofen, Monoamine Oxidase Inhibitors, Neuroprotective Agents, Selegiline.
- Adolescent, Adult, Drug Therapy, Combination, Female, Genotype, Heterozygote Detection, Humans, Long-Term Care, Male, Middle Aged, Polymerase Chain Reaction, Reference Values, Trinucleotide Repeats.
Abstract
A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. When selegiline was stopped after 9 years of treatment, abnormal involuntary movements improved to pretreatment level and psychiatric behaviour returned to normal. Monoamine oxidase‐B platelet activity was low in this patient. © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10641
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003691
- to stream Istex, to step Curation: 003691
- to stream Istex, to step Checkpoint: 002805
- to stream PubMed, to step Corpus: 003567
- to stream PubMed, to step Curation: 003567
- to stream PubMed, to step Checkpoint: 003572
- to stream Ncbi, to step Merge: 000C97
- to stream Ncbi, to step Curation: 000C97
- to stream Ncbi, to step Checkpoint: 000C97
- to stream Main, to step Merge: 005782
- to stream PascalFrancis, to step Corpus: 002224
- to stream PascalFrancis, to step Curation: 000A97
- to stream PascalFrancis, to step Checkpoint: 002257
- to stream Main, to step Merge: 005A95
- to stream Main, to step Curation: 003E24
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adverse effects of dopamine potentiation by long‐term treatment with selegiline</title><author><name sortKey="Hollan, Susan" sort="Hollan, Susan" uniqKey="Hollan S" first="Susan" last="Hollán">Susan Hollán</name></author><author><name sortKey="Vecsei, Laszl" sort="Vecsei, Laszl" uniqKey="Vecsei L" first="Lászl" last="Vécsei">Lászl Vécsei</name></author><author><name sortKey="Magyar, Kalman" sort="Magyar, Kalman" uniqKey="Magyar K" first="Kálmán" last="Magyar">Kálmán Magyar</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:95E24F7434E6BE62A0996F41BAB7EC3F30338AE5</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.10641</idno><idno type="url">https://api.istex.fr/document/95E24F7434E6BE62A0996F41BAB7EC3F30338AE5/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003691</idno><idno type="wicri:Area/Istex/Curation">003691</idno><idno type="wicri:Area/Istex/Checkpoint">002805</idno><idno type="wicri:doubleKey">0885-3185:2004:Hollan S:adverse:effects:of</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:14743370</idno><idno type="wicri:Area/PubMed/Corpus">003567</idno><idno type="wicri:Area/PubMed/Curation">003567</idno><idno type="wicri:Area/PubMed/Checkpoint">003572</idno><idno type="wicri:Area/Ncbi/Merge">000C97</idno><idno type="wicri:Area/Ncbi/Curation">000C97</idno><idno type="wicri:Area/Ncbi/Checkpoint">000C97</idno><idno type="wicri:doubleKey">0885-3185:2004:Hollan S:adverse:effects:of</idno><idno type="wicri:Area/Main/Merge">005782</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:04-0233626</idno><idno type="wicri:Area/PascalFrancis/Corpus">002224</idno><idno type="wicri:Area/PascalFrancis/Curation">000A97</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002257</idno><idno type="wicri:doubleKey">0885-3185:2004:Hollan S:adverse:effects:of</idno><idno type="wicri:Area/Main/Merge">005A95</idno><idno type="wicri:Area/Main/Curation">003E24</idno><idno type="wicri:Area/Main/Exploration">003E24</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Adverse effects of dopamine potentiation by long‐term treatment with selegiline</title><author><name sortKey="Hollan, Susan" sort="Hollan, Susan" uniqKey="Hollan S" first="Susan" last="Hollán">Susan Hollán</name><affiliation wicri:level="3"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Cell Biology, National Blood Transfusion Service, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author><author><name sortKey="Vecsei, Laszl" sort="Vecsei, Laszl" uniqKey="Vecsei L" first="Lászl" last="Vécsei">Lászl Vécsei</name><affiliation wicri:level="1"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Neurology, A. Szent‐Györgyi University, Szeged</wicri:regionArea><wicri:noRegion>Szeged</wicri:noRegion></affiliation></author><author><name sortKey="Magyar, Kalman" sort="Magyar, Kalman" uniqKey="Magyar K" first="Kálmán" last="Magyar">Kálmán Magyar</name><affiliation wicri:level="3"><country xml:lang="fr">Hongrie</country><wicri:regionArea>Department of Pharmacodynamics, Semmelweis University, Budapest</wicri:regionArea><placeName><settlement type="city">Budapest</settlement><region nuts="2">Hongrie centrale</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-01">2004-01</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="107">107</biblScope><biblScope unit="page" to="109">109</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">95E24F7434E6BE62A0996F41BAB7EC3F30338AE5</idno><idno type="DOI">10.1002/mds.10641</idno><idno type="ArticleID">MDS10641</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Amine oxidase (flavin-containing)</term><term>Anemia, Hemolytic, Congenital (enzymology)</term><term>Anemia, Hemolytic, Congenital (genetics)</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Baclofen (adverse effects)</term><term>Baclofen (therapeutic use)</term><term>Basal Ganglia (drug effects)</term><term>Basal Ganglia Diseases (drug therapy)</term><term>Basal Ganglia Diseases (enzymology)</term><term>Basal Ganglia Diseases (genetics)</term><term>Blood Platelets (enzymology)</term><term>Catecholamine</term><term>Dopamine</term><term>Dopamine agonist</term><term>Drug Therapy, Combination</term><term>Dyskinesia, Drug-Induced (diagnosis)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Dystonia Musculorum Deformans (drug therapy)</term><term>Dystonia Musculorum Deformans (enzymology)</term><term>Dystonia Musculorum Deformans (genetics)</term><term>Enzyme inhibitor</term><term>Female</term><term>Genotype</term><term>Glyceraldehyde-3-Phosphate Dehydrogenases (deficiency)</term><term>Glyceraldehyde-3-Phosphate Dehydrogenases (genetics)</term><term>Heterozygote Detection</term><term>Humans</term><term>Long-Term Care</term><term>MAO B inhibitor</term><term>Male</term><term>Middle Aged</term><term>Monoamine Oxidase (blood)</term><term>Monoamine Oxidase (genetics)</term><term>Monoamine Oxidase Inhibitors (adverse effects)</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Nerve Tissue Proteins (genetics)</term><term>Nervous system diseases</term><term>Neurologic Examination (drug effects)</term><term>Neuroprotective Agents (adverse effects)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Nuclear Proteins (genetics)</term><term>Polymerase Chain Reaction</term><term>Potentiation</term><term>Proteins (genetics)</term><term>Psychoses, Substance-Induced (diagnosis)</term><term>Psychoses, Substance-Induced (etiology)</term><term>Reference Values</term><term>Selegiline</term><term>Selegiline (adverse effects)</term><term>Selegiline (therapeutic use)</term><term>TPI defect</term><term>Treatment</term><term>Trinucleotide Repeats</term><term>monoamine oxidase‐B</term><term>selegiline</term><term>triosephosphate isomerase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Baclofen</term><term>Monoamine Oxidase Inhibitors</term><term>Neuroprotective Agents</term><term>Selegiline</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Monoamine Oxidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Glyceraldehyde-3-Phosphate Dehydrogenases</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Basal Ganglia Diseases</term><term>Dystonia Musculorum Deformans</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Anemia, Hemolytic, Congenital</term><term>Basal Ganglia Diseases</term><term>Blood Platelets</term><term>Dystonia Musculorum Deformans</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Anemia, Hemolytic, Congenital</term><term>Basal Ganglia Diseases</term><term>Dystonia Musculorum Deformans</term><term>Glyceraldehyde-3-Phosphate Dehydrogenases</term><term>Monoamine Oxidase</term><term>Nerve Tissue Proteins</term><term>Nuclear Proteins</term><term>Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Baclofen</term><term>Monoamine Oxidase Inhibitors</term><term>Neuroprotective Agents</term><term>Selegiline</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Drug Therapy, Combination</term><term>Female</term><term>Genotype</term><term>Heterozygote Detection</term><term>Humans</term><term>Long-Term Care</term><term>Male</term><term>Middle Aged</term><term>Polymerase Chain Reaction</term><term>Reference Values</term><term>Trinucleotide Repeats</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Amine oxidase (flavin-containing)</term><term>Catécholamine</term><term>Dopamine</term><term>IMAO B</term><term>Inhibiteur enzyme</term><term>Potentialisation</term><term>Stimulant dopaminergique</term><term>Système nerveux pathologie</term><term>Sélégiline</term><term>Traitement</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A patient with triosephosphate isomerase (TPI) deficiency exhibited worsening of abnormal involuntary movements of the dystonic type and developed psychiatric symptoms while on selegiline. When selegiline was stopped after 9 years of treatment, abnormal involuntary movements improved to pretreatment level and psychiatric behaviour returned to normal. Monoamine oxidase‐B platelet activity was low in this patient. © 2003 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Hongrie</li></country><region><li>Hongrie centrale</li></region><settlement><li>Budapest</li></settlement></list><tree><country name="Hongrie"><region name="Hongrie centrale"><name sortKey="Hollan, Susan" sort="Hollan, Susan" uniqKey="Hollan S" first="Susan" last="Hollán">Susan Hollán</name></region><name sortKey="Magyar, Kalman" sort="Magyar, Kalman" uniqKey="Magyar K" first="Kálmán" last="Magyar">Kálmán Magyar</name><name sortKey="Vecsei, Laszl" sort="Vecsei, Laszl" uniqKey="Vecsei L" first="Lászl" last="Vécsei">Lászl Vécsei</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003E24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:95E24F7434E6BE62A0996F41BAB7EC3F30338AE5
|texte= Adverse effects of dopamine potentiation by long‐term treatment with selegiline
}}
| This area was generated with Dilib version V0.6.23. |  |